Authors
Rosaria Di Lorenzo, Andrea Santoro, Jessica Bonisoli, Carolina Bottone, Paola Ferri, Sergio Rovesti
Published in
Therapeutic advances in drug safety. Volume 17. Pages 20420986261430214. Epub Mar 31, 2026.
Abstract
Many antipsychotic medications are responsible for prolonging QTc, a risk factor for sudden death, which is one of the main causes of reduced life expectancy in patients with mental health disorders.
To evaluate the cardiac safety profile of clotiapine in a naturalistic setting.
This observational, retrospective study included 70 subjects hospitalized at the Service of Psychiatry Diagnosis and Care in Modena from February 1, 2023 to July 31, 2024, treated with clotiapine.
Demographic and clinical data were collected, along with electrocardiographic measurements (QTc) taken at the start of treatment (T0), after at least 7 days of therapy (T1), and at further follow-up (T2) after 7-21 days. Prolongation was considered when QTc exceeded 500 ms or an increase of 60 ms compared to baseline, according to international standards.
QTc prolongation was limited (m = 4.59 ms), representing an increase of 1.07%, without reaching thresholds of significant clinical risk. Subjects with an increase equal to or greater than the median (M = 3.5) of QTc increase at T1 accounted for half of the sample, and only one patient had an increase greater than 60 ms.
Clotiapine treatment, also in combination with haloperidol, had minimal prolongation of QTc within the limits of clinical safety. A stabilization of QTc over time was observed, indicating a possible adaptation to treatment. Methodological limitations of this study call for further research.
PMID:
41930229
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0